IDEXX Laboratories Announces Third Quarter Results
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
Q3 revenue $1,214M, up 10% organic; EPS $4.01, up 18%; 2026 revenue guidance raised $32M at midpoint to $4,741M-$4,767M.
Historical context for IDXX
Across the 26 sessions after earlier IDXX headlines, the stock closed higher 15 times and lower 11 times, with a median move of 1.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IDXX | SPY |
|---|---|---|---|
| Oct 16, 2026 | Goldman initiated coverage on IDEXX Labs with a new price target | +2.4% | -1.1% |
| Oct 12, 2026 | KeyBanc Capital Markets initiated coverage on IDEXX Labs | +1.1% | -0.1% |
| Oct 1, 2026 | IDEXX Laboratories to Release 2026 Third Quarter Financial Results | -0.9% | +0.2% |
| Sep 30, 2026 | Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories | -2.1% | -0.2% |
| Sep 17, 2026 | IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection | -1.4% | +1.1% |
| Sep 16, 2026 | IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence | +0.6% | -0.4% |
Quantisnow market dataNASDAQ
IDXX
IDEXX Laboratories Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Listed since
- 1991
Get push alerts for IDXX
Full IDXX profile on Quantisnow Follow IDXX and get a push notification the moment its next story breaks.